search
Back to results

A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL). (Part B)

Primary Purpose

Cutaneous T-cell Lymphoma (CTCL)

Status
Terminated
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
CDK-003
Sponsored by
Codiak BioSciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cutaneous T-cell Lymphoma (CTCL)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Histologically confirmed CTCL as per Olsen et al, 2011 or per algorithm for diagnosis of early MF as per Pimpinelli et al, 2005.
  2. Patient-participants with Stage IA-IIB CTCL (MF) with injectable lesions (patches, plaques, or tumors), who have relapsed or refractory disease following at least 1 prior standard treatment. Patient-participants who are unsuitable to receive standard treatment or who have declined standard treatment are also eligible.
  3. Patient-participants must have ≥ 1 treatable/measurable lesion(s) for injection as per Olsen criteria.
  4. Understands and is able to comply with the study requirements and has signed the informed consent form.
  5. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  6. Life expectancy of at least 6 months.
  7. Age 18 years or older at the time of signing the informed consent form.
  8. Acceptable liver function:

    1. Bilirubin equal 1.5x ULN.
    2. AST (SGOT), ALT (SGPT) equal 3.0x ULN.
  9. Acceptable renal function:

    a. Serum creatinine ≤ 1.5x ULN.

  10. Acceptable hematologic status:

    1. Absolute neutrophil count - 1500 cells/mm3
    2. Platelet count - 100,000 /mm3
    3. Hemoglobin - 9 g/dL.
  11. Acceptable coagulation status: international normalized ratio ≤ 1.5 ULN. Patient-participants on therapeutic doses of vitamin K antagonists (eg, warfarin) or direct oral anticoagulants (eg, direct thrombin or direct factor Xa inhibitors) are not eligible.

    Anticoagulation with low molecular weight heparins is permitted.

  12. Women of child-producing potential agree to use highly effective contraceptive methods (see Appendix C for details) for one complete menstrual cycle (or at least 30 days) prior to the first dose of CDK-003 until 6 months following the last dose of CDK-003, and avoid egg donation from the time of the first dose of CDK-003 until 6 months following the last dose of CDK-003. A female participant is considered to be of child-producing potential unless she:

    1. has had a hysterectomy or bilateral oophorectomy or
    2. is age ≥ 60 years and is amenorrhoeic or
    3. is age < 60 years and has been amenorrhoeic for ≥ 12 months (including no irregular menses or spotting) in the absence of any medication which induces a menopausal state and has documented ovarian failure by serum estradiol and follicle-stimulating hormone levels within the institutional laboratory postmenopausal range).
  13. A negative pregnancy test (if a woman of child-producing potential) within 72 hours prior to the first dose of CDK-003.
  14. Men of child-producing potential agree to use highly effective contraceptive methods and avoid sperm donation from the time of the first dose of CDK-003 until 6 months following the last dose. Male patient-participants must use a condom when engaged in intercourse during the study and for 6 months after the last dose of study drug.

    A man is considered to be of child-producing potential unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.

  15. Patient-participant agrees to have a pre-treatment tumor biopsy during the Screening Period, and 2 on-treatment tumor biopsies of the same lesion.

Exclusion Criteria:

  1. Patient-participants with CTCL disease involving N3 nodes.
  2. Clinically significant ongoing AEs that have not returned to baseline or to Grade 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 during the Screening Period.
  3. Received nitrogen mustard, PUVA, narrow band UVB light therapy, carmustine (BCNU), other systemic therapies, radiation therapy or investigational agents for CTCL within 21 days of Day 1.
  4. Received systemic corticosteroids within 28 days of Day 1.
  5. Use of topical corticosteroids on any of the target lesions for CDK-003 injection or non-injected target lesion within 28 days of Day 1. Topical corticosteroid use is permitted for non-target lesions.
  6. Major surgery within 2 months or minor surgery (excluding tumor biopsies) within 14 day prior to Day 1.
  7. Clinically significant cardiovascular disease including but not limited to myocardial infarction or stroke within the past 6 months prior to Day 1, New York Heart Association Class III or IV heart failure, uncontrolled arrhythmia, or severe aortic stenosis. Sponsor approval of patient-participants with an arrhythmia is required.
  8. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.

    Prophylactic antibiotics are acceptable.

  9. Prior organ or stem cell transplant.
  10. Primary immune deficiency.
  11. Pregnant or nursing women.
  12. Positive test for HBsAg, HCV Ab, or HIV Ab during the Screening Period.
  13. Unwillingness or inability to comply with procedures required in this protocol.
  14. Serious non-malignant disease (e.g., liver failure, ongoing infection requiring intravenous treatment, psychological illness, autoimmune disease including but not limited to inflammatory bowel disease, or other conditions) or social situations that, in the opinion of the Investigator and/or the Sponsor, could compromise protocol objectives or patient participant safety or the ability of the patient-participant to comply with the protocol.
  15. History of another malignancy, unless potentially curative treatment has been performed. Sponsor approval is required. Patient-participants with early stage prostate cancer on active surveillance may be enrolled with Sponsor approval.
  16. Currently receiving any other anti-cancer or investigational agent.

Sites / Locations

  • University Hospital Birmingham
  • Beatson West of Scotland Cancer Centre Haematology
  • Guys Hospital/ Guy's Cancer Centre
  • The Christie

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CDK-003

Arm Description

CDK-003 administered subcutaneously every 2 weeks.

Outcomes

Primary Outcome Measures

Primary Outcome
To determine the safety, tolerability, and DLTs of CDK-003 monotherapy following multiple ascending dose escalation in patient-participants with CTCL
Primary Outcome
To identify a recommended phase 2 dose (RP2D) for CDK-003 monotherapy.

Secondary Outcome Measures

Secondary Outcome
To evaluate the preliminary anti-tumor activity of CDK-003 monotherapy

Full Information

First Posted
December 1, 2021
Last Updated
August 30, 2022
Sponsor
Codiak BioSciences
search

1. Study Identification

Unique Protocol Identification Number
NCT05156229
Brief Title
A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).
Acronym
Part B
Official Title
A Phase 1/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CDK-003 in Healthy Adult Participants and Intralesionally Administered CDK-003 in Patients With Cutaneous T-cell Lymphoma (CTCL)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Terminated
Why Stopped
PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety profile. Proceeding to Phase II did not require additional data from this Phase I Dose-Finding study.
Study Start Date
September 6, 2021 (Actual)
Primary Completion Date
August 24, 2022 (Actual)
Study Completion Date
August 24, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Codiak BioSciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase 1, dose escalation study to assess the safety, tolerability, pharmacokinetic and pharmacodynamic effects of CDK-003. The study is performed in two parts: Part A is a randomized, double-blind, placebo-controlled, single ascending dose study of CDK-003 in healthy adult male participants, and Part B is a single arm, open-label, multiple ascending dose in patient-participants with CTCL. Dose escalation in the study will only occur after satisfactory review of all available predefined data by the Safety Review Committee. Part A is complete and this entry describes Part B only.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cutaneous T-cell Lymphoma (CTCL)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CDK-003
Arm Type
Experimental
Arm Description
CDK-003 administered subcutaneously every 2 weeks.
Intervention Type
Biological
Intervention Name(s)
CDK-003
Intervention Description
CDK-003 administered subcutaneously
Primary Outcome Measure Information:
Title
Primary Outcome
Description
To determine the safety, tolerability, and DLTs of CDK-003 monotherapy following multiple ascending dose escalation in patient-participants with CTCL
Time Frame
up to 2 years
Title
Primary Outcome
Description
To identify a recommended phase 2 dose (RP2D) for CDK-003 monotherapy.
Time Frame
up to 2 years
Secondary Outcome Measure Information:
Title
Secondary Outcome
Description
To evaluate the preliminary anti-tumor activity of CDK-003 monotherapy
Time Frame
up to 2 years
Other Pre-specified Outcome Measures:
Title
Exploratory Outcome
Description
To evaluate potential pharmacodynamic biomarkers associated with treatment with CDK-003 monotherapy that may correlate with any anti-tumour effect.
Time Frame
up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed CTCL as per Olsen et al, 2011 or per algorithm for diagnosis of early MF as per Pimpinelli et al, 2005. Patient-participants with Stage IA-IIB CTCL (MF) with injectable lesions (patches, plaques, or tumors), who have relapsed or refractory disease following at least 1 prior standard treatment. Patient-participants who are unsuitable to receive standard treatment or who have declined standard treatment are also eligible. Patient-participants must have ≥ 1 treatable/measurable lesion(s) for injection as per Olsen criteria. Understands and is able to comply with the study requirements and has signed the informed consent form. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Life expectancy of at least 6 months. Age 18 years or older at the time of signing the informed consent form. Acceptable liver function: Bilirubin equal 1.5x ULN. AST (SGOT), ALT (SGPT) equal 3.0x ULN. Acceptable renal function: a. Serum creatinine ≤ 1.5x ULN. Acceptable hematologic status: Absolute neutrophil count - 1500 cells/mm3 Platelet count - 100,000 /mm3 Hemoglobin - 9 g/dL. Acceptable coagulation status: international normalized ratio ≤ 1.5 ULN. Patient-participants on therapeutic doses of vitamin K antagonists (eg, warfarin) or direct oral anticoagulants (eg, direct thrombin or direct factor Xa inhibitors) are not eligible. Anticoagulation with low molecular weight heparins is permitted. Women of child-producing potential agree to use highly effective contraceptive methods (see Appendix C for details) for one complete menstrual cycle (or at least 30 days) prior to the first dose of CDK-003 until 6 months following the last dose of CDK-003, and avoid egg donation from the time of the first dose of CDK-003 until 6 months following the last dose of CDK-003. A female participant is considered to be of child-producing potential unless she: has had a hysterectomy or bilateral oophorectomy or is age ≥ 60 years and is amenorrhoeic or is age < 60 years and has been amenorrhoeic for ≥ 12 months (including no irregular menses or spotting) in the absence of any medication which induces a menopausal state and has documented ovarian failure by serum estradiol and follicle-stimulating hormone levels within the institutional laboratory postmenopausal range). A negative pregnancy test (if a woman of child-producing potential) within 72 hours prior to the first dose of CDK-003. Men of child-producing potential agree to use highly effective contraceptive methods and avoid sperm donation from the time of the first dose of CDK-003 until 6 months following the last dose. Male patient-participants must use a condom when engaged in intercourse during the study and for 6 months after the last dose of study drug. A man is considered to be of child-producing potential unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. Patient-participant agrees to have a pre-treatment tumor biopsy during the Screening Period, and 2 on-treatment tumor biopsies of the same lesion. Exclusion Criteria: Patient-participants with CTCL disease involving N3 nodes. Clinically significant ongoing AEs that have not returned to baseline or to Grade 1 National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 during the Screening Period. Received nitrogen mustard, PUVA, narrow band UVB light therapy, carmustine (BCNU), other systemic therapies, radiation therapy or investigational agents for CTCL within 21 days of Day 1. Received systemic corticosteroids within 28 days of Day 1. Use of topical corticosteroids on any of the target lesions for CDK-003 injection or non-injected target lesion within 28 days of Day 1. Topical corticosteroid use is permitted for non-target lesions. Major surgery within 2 months or minor surgery (excluding tumor biopsies) within 14 day prior to Day 1. Clinically significant cardiovascular disease including but not limited to myocardial infarction or stroke within the past 6 months prior to Day 1, New York Heart Association Class III or IV heart failure, uncontrolled arrhythmia, or severe aortic stenosis. Sponsor approval of patient-participants with an arrhythmia is required. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy. Prophylactic antibiotics are acceptable. Prior organ or stem cell transplant. Primary immune deficiency. Pregnant or nursing women. Positive test for HBsAg, HCV Ab, or HIV Ab during the Screening Period. Unwillingness or inability to comply with procedures required in this protocol. Serious non-malignant disease (e.g., liver failure, ongoing infection requiring intravenous treatment, psychological illness, autoimmune disease including but not limited to inflammatory bowel disease, or other conditions) or social situations that, in the opinion of the Investigator and/or the Sponsor, could compromise protocol objectives or patient participant safety or the ability of the patient-participant to comply with the protocol. History of another malignancy, unless potentially curative treatment has been performed. Sponsor approval is required. Patient-participants with early stage prostate cancer on active surveillance may be enrolled with Sponsor approval. Currently receiving any other anti-cancer or investigational agent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julia Scarisbrick, MD
Organizational Affiliation
University Hospital Birmingham NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Birmingham
City
Birmingham
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Facility Name
Beatson West of Scotland Cancer Centre Haematology
City
Glasgow
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Facility Name
Guys Hospital/ Guy's Cancer Centre
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
The Christie
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).

We'll reach out to this number within 24 hrs